Stroke
Also known as: Brain attack, CVA, Cerebrovascular Accident, Infarction, Bleed
Methodology & AI Transparency ⓘ
Stroke Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a stroke? A stroke happens when there is a loss of blood flow to part of the brain.
- 2 Real-world patient consensus: Mapped to Neurology, Stroke & Movement Disorders under ICD-10-CM I63.9 for Stroke clinical workups.
- 3 Typical cash cost range: Primary evaluation for Stroke incorporates comprehensive cranial [Stroke I63.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Stroke monitoring tracks Carotid Duplex / in Stroke (I63.9: Cerebral Perfusion) toward No hemodynamically significant stenosis (I63.9).
Ask our AI Specialists anything about Stroke
What Is Stroke?
What is a stroke? A stroke happens when there is a loss of blood flow to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die within a few minutes. This can cause lasting brain damage, long-term disability, or even death. If you think that you or someone else is having a stroke, call 911 right away. Immediate treatment may save someone's life and increase the chances for successful rehabilitation and recovery. What are the types of stroke? There are two types of stroke: Ischemic stroke is caused by a blood clot that blocks or plugs a blood vessel in the brain.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Stroke (I63.9) center on demyelination [Stroke I63.9]. Cross-referenced with NIH MeSH (Stroke), targeted brain & neurology interventions aim to normalize Carotid Duplex / in Stroke (I63.9: Cerebral Perfusion).
Common Symptoms & Clinical Signs
- • Hemorrhagic stroke is caused by a blood vessel that breaks and bleeds into the brain
- • High blood pressure . This is the primary risk factor for a stroke
- • Presentation of Stroke (I63.9): numbness, paresthesia, or in Stroke (I63.9: visual field/speech changes)
- • Secondary Stroke clinical sign: muscle stiffness, spasticity, in Stroke (I63.9: or fatigable neuromuscular)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Stroke Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I63.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Carotid Duplex / in Stroke (I63.9: Cerebral Perfusion) | No hemodynamically significant stenosis (I63.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Stroke (I63.9: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (I63.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Stroke (I63.9: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (I63.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Stroke
Treatment selection for Stroke depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Stroke)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Inclisiran for the Treatment of high: What a 3,660-Participant Study Found In conclusions, in patients with high cholesterol, inclisiran decreased LDL level by 51% without significant adverse effects. The American journal of cardiology • 2020-11-01 • Meta-Analysis | N = 3,660 | 99/100 | PMID 32892993 ↗ |
| New Insights on Telmisartan to prevent recurrent stroke and heart and blood vessel: What a 20,332-Participant Study Found Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major heart and blood vessel events, or diabetes. The New England journal of medicine • 2008-09-18 • Randomized Controlled Trial | N = 20,332 | 96/100 | PMID 18753639 ↗ |
| New Insights on Utility of Progression Independent of Relapse Activity as a Trial Outcome in: What a 2,113-Participant Study Found Our analysis included 2,113 participants, 42.4% of whom developed radiologic disease activity during follow-up. Neurology • 2025-01-28 • Phase III Randomized Trial | N = 2,113 | 96/100 | PMID 39960455 ↗ |
| New Insights on Clinical real-world benefits and safety of Evolocumab in High-Risk Patients: What a 529-Participant Study Found A total of 27 564 patients (75.4% men and 24.6% women; mean [SD] age, 62.5 [9.0] years) were included in the analysis. JAMA cardiology • 2017-12-01 • Randomized Controlled Trial | N = 529 | 93/100 | PMID 29117276 ↗ |
Stroke Patient Community & “People Like Me” Threads
Filter Stroke community threads and patient logs by age, biological sex, dosage, and treatment duration.